Sean Shannon, MD
Rheumatology · Baton Rouge, LANPI 1619995487
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,655 of the $157,167 with a category attached, or 74.2%. AbbVie accounts for 88.8% of it on its own, with 35 other manufacturers making up the rest. Among rheumatology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 991 payments — averaging $158.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$140K
- Regeneron Healthcare Solutions, Inc.$4K
- Amgen$3K
- UCB, Inc.$1K
- Aurinia Pharma U.S., Inc.$1K
- Sanofi$1K
- plus $7K from 30 others
What the payments were for
- Speaking & faculty fees$116,65574%
- Travel & lodging$19,97613%
- Food & beverage$20,40813%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 324 | $139,548 |
| Regeneron Healthcare Solutions, Inc. | 25 | $3,567 |
| Amgen(2 entities) | 160 | $3,333 |
| UCB, Inc. | 63 | $1,418 |
| Aurinia Pharma U.S., Inc. | 53 | $1,172 |
| Sanofi | 8 | $1,060 |
| Radius Health, Inc. | 39 | $900 |
| Lilly USA, LLC | 44 | $845 |
| AstraZeneca(2 entities) | 26 | $753 |
| Pfizer | 41 | $646 |
| GSK | 36 | $526 |
| Johnson & Johnson | 27 | $513 |
| Novartis | 27 | $476 |
| Boehringer Ingelheim | 17 | $451 |
| E.r. Squibb & Sons, L.L.C. | 21 | $422 |
| Genentech USA, Inc. | 19 | $340 |
| Fresenius Kabi USA, LLC | 13 | $326 |
| ANI Pharmaceuticals, Inc. | 6 | $143 |
| Medexus Pharma, Inc. | 11 | $115 |
| Actelion Pharmaceuticals US, Inc. | 5 | $97 |
| Hikma Pharmaceuticals USA | 4 | $93 |
| Organon | 5 | $92 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $63 |
| Bristol Myers Squibb | 2 | $44 |
| Almatica Pharma LLC | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Sandoz | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Celltrion USA Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Genentech, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,167 in reported general payments places this provider in the 90th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 147 | $1,160,369 |
| Humira(Cf) PenAdalimumab | 62 | $438,393 |
| Humira(Cf)Adalimumab | 24 | $165,287 |
| Xeljanz XrTofacitinib Citrate | 27 | $145,960 |
| LupkynisVoclosporin | 15 | $133,936 |
| Humira PenAdalimumab | 13 | $104,645 |
| TymlosAbaloparatide | 34 | $88,545 |
| Enbrel MiniEtanercept | 11 | $82,275 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $78,318 |
| BenlystaBelimumab | 16 | $74,439 |
| ActemraTocilizumab | 14 | $63,069 |
| ProliaDenosumab | 11 | $19,234 |
| Mycophenolate Mofetil | 60 | $11,675 |
| Hydroxychloroquine Sulfate | 191 | $9,630 |
| MethotrexateMethotrexate Sodium | 197 | $2,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $139,548 | $1,325,656171 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $1,172 | $133,93615 claims |
| Radius Health, Inc.Tymlos | $900 | $88,54534 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,418 | $78,31814 claims |
| GSKBenlysta | $526 | $74,43916 claims |
| Genentech, Inc.Actemra | $14 | $63,06914 claims |
| AmgenProlia | $3,333 | $19,23411 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $21 | $1,17925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Baton Rouge
- Stephen LindseyBaton Rouge$130K
- Randall BeylBaton Rouge$112K
- Chad HilleBaton Rouge$52K
- Ronald CerutiBaton Rouge$29K
- Joseph NesheiwatBaton Rouge$18K
- Jen ErbilBaton Rouge$17K
- Hector MenaBaton Rouge$15K
- Stephen PolletBaton Rouge$14K
- Khanh HoBaton Rouge$12K
- Angele BourgBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.